Treatment of antibody-mediated rejection in kidney transplant recipients: A single-center experience with a bortezomib-based regimen

Experimental and Clinical Transplantation

Volumn 10, Issue 6, 2012, Pages 609-613

  Nigos, Janice G ^a   Arora, Swati ^a   Nath, Parineesha ^a   Hussain, Sabiha M ^a   Marcus, Richard J ^a   Ko, Tina Y ^a   Sureshkumar, Kalathil K ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Bortezomib; Donor specific antibodies; Humoral rejection; Kidney transplant; Plasma cells

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; COMPLEMENT COMPONENT C4D; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; MEDICAL RECORD REVIEW; PLASMA CELL; PLASMAPHERESIS; REPEATED DRUG DOSE; SCHOOL CHILD; SINGLE DRUG DOSE; STAINING;

ADULT; ANTIBODIES; BORONIC ACIDS; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; PLASMA CELLS; PROTEASOME INHIBITORS; PYRAZINES; RETROSPECTIVE STUDIES; TISSUE DONORS;

EID: 84871270171     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2012.0131     Document Type: Article

References (13)

1. Rafiq MA, de Boccardo G, Schröppel B, et al. Differential outcomes in 3 types of acute antibody-mediated rejection. Clin Transplant. 2009;23(6):951-957.
2. Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens. 2002;11(6):609-618.
3. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant. 2007;7(3):518-526.
4. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86(12):1754-1761.
5. Sureshkumar KK, Hussain SM, Marcus RJ, et al. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation. Clin Nephrol. 2012;77(3):246-253.
6. Walsh RC, Alloway RR, Girnita AL, Woodle ES. Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int. 2012;81(11):1067-1074.
7. Lucas JG, Co JP, Nwaogwugwu UT, Dosani I, Sureshkumar KK. Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother. 2011;12(4):579-592.
8. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant. 2004;4(6):996-1001.
9. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007;67(4):1783-1792.
10. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant. 2009;9(1):201-209.
11. Everly MJ, Everly JJ, Susskind B, et al. Proteasome inhibition reduces donor-specific antibody levels. Transplant Proc. 2009;41(1):105-107.
12. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant. 2010;10(3):681-686.
13. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation. 2009;87(10):1555-1561.